{"prompt": "['Appendix 1', 'Schedule of Activities (cont.)', 'aa. Serum and plasma EDTA samples for bone and joint biomarkers must be collected after fasting (no food or drink other than water for at', 'least', '8', 'hours', 'prior to the blood draw). Ideally these samples should be collected in the morning (before noon), in order to control for diurnal variation.', 'Please', 'consult', 'the Central Laboratory Services Manual for details. The selection of exploratory bone and joint biomarkers to be tested will build on findings from', 'biomarker analyses in other emicizumab trials and may include CTX-1, OPG, P1NP, and soluble RANK-L (see Appendix 2', 'Schedule of Biomarker Samples', 'bb. ). Samples will be analysed by the central laboratory.', 'cc. Additional laboratory assessments: In the event of a breakthrough bleed that is treated with bypassing agents, it is recommended that the following laboratory tests', 'will be performed within 24-48 hours of initial bypassing agent use (these tests will be conducted so that the investigator can monitor the patient for potential', 'thromboembolic events and microangiopathic hemolytic anemia or TMA). These tests include platelet count, serum creatinine, LDH and schistocytes. A plasma sample', 'should also be provided for central laboratory monitoring of prothrombin fragment F1+2, fibrinogen and D-dimer. Samples for these tests should ideally be', 'analysed at the central laboratory. Exceptionally in urgent situations where results are required quickly, local laboratory testing can be used, with results recorded in', 'the eCRF. For patients who require multiple doses of bypassing agents, laboratory monitoring should be performed every 24-48 hours until 24-48 hours after the last', 'dose of bypassing agents is administered to treat a specific bleed. If applicable, laboratory results should be recorded in the unscheduled visit eCRFs.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '163 / Protocol MO39129, Version 3']['Appendix 2', 'Schedule of Biomarker Samples', 'Time', 'Sample', 'Visit [a]', 'window', 'Biomarker assays [b]', 'Safety biomarkers [c]', 'Week 1', 'Day 1', 'May include, but are not limited to, D-dimer', 'Week 5', '+ 2 days', '3 months', '+1 7 days', '6 months', '+ 7 days', '12 months', '+ 14 days', '18 months', '+ 30 days', 'Study completion', '+ 30 days', 'Safety Follow-up', 'Visit (if applicable)', 'Safety coagulation', 'Week 1', 'Day 1', 'FVIII:Ag, FIX:Ag and FX:Ag', 'system biomarkers [c]', 'Week 5', '+ 2 days', 'PD biomarkers [c]', 'Week 1', 'Day 1', 'Will include, but are not limited to:', 'FVIII inhibitor titer, Modified aPTT (one-', 'Week 5', '+ 2 days', 'stage), FVIII activity', '3 months', '+ 7 days', '6 months', '+ 7 days', '12 months', '+ 14 days', '18 months', '+ 30 days', 'Study completion', '+ 30 days', 'Bone and joint', 'Week 1', 'Day 1', 'Exploratory biomarkers of bone turnover', 'biomarkers (fasting) [d]', 'and joint health [e]', '6 months', '+ 7 days', '18 months', '30 days', 'Study completion', '+ 30 days', 'aPTT=activated partial thromboplastin time; CTX-1=C-terminal telopeptide of collagen 1; CWA=clot', 'waveform', 'analysis;', 'IDTA=ethylenediaminetetraacetic', 'acid;', 'DPG=osteoprotegerin;', 'P1NP=procollagen type 1 amino-terminal propeptide; PD=pharmacodynamic; RANK-L=receptor', 'activator of nuclear factor kappa-B ligand', 'a.', 'All samples are to be collected within 2 hours prior to emicizumab injection (if applicable) unless', 'otherwise specified.', 'b. Assays that will be tested are listed. Blood volumes and processing procedures will be specified', 'in the Central Laboratory Services Manual. Biomarker assessments will be conducted at the central', \"laboratory. Additional analysis will be performed at a local laboratory, as per the investigator's discretion.\", 'c. Samples are required to be citrate plasma. Additional plasma will be collected for future', 'exploratory research, which may include tests such as CWA and others.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '164 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}